PL4225306T3 - Zastosowanie soli siarczanowych n‐(3‐(4‐(3‐(diizobutyloamino)propylo)piperazyn‐1‐ylo)propylo)‐1h‐benzo[d]imidazolo‐2‐aminy i ich solwatów do leczenia chorób neuronu ruchowego i zaburzeń płytki nerwowo-mięśniowej - Google Patents
Zastosowanie soli siarczanowych n‐(3‐(4‐(3‐(diizobutyloamino)propylo)piperazyn‐1‐ylo)propylo)‐1h‐benzo[d]imidazolo‐2‐aminy i ich solwatów do leczenia chorób neuronu ruchowego i zaburzeń płytki nerwowo-mięśniowejInfo
- Publication number
- PL4225306T3 PL4225306T3 PL21782766.6T PL21782766T PL4225306T3 PL 4225306 T3 PL4225306 T3 PL 4225306T3 PL 21782766 T PL21782766 T PL 21782766T PL 4225306 T3 PL4225306 T3 PL 4225306T3
- Authority
- PL
- Poland
- Prior art keywords
- propyl
- diisobutylamino
- piperazin
- imidazol
- solvates
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/30—Nitrogen atoms not forming part of a nitro radical
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20306168 | 2020-10-07 | ||
| PCT/EP2021/077641 WO2022074093A1 (en) | 2020-10-07 | 2021-10-07 | Use of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine sulphate salts and solvates thereof for the treatment of motor neuron diseases and neuromuscular junction disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL4225306T3 true PL4225306T3 (pl) | 2025-08-04 |
Family
ID=73005517
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL21782766.6T PL4225306T3 (pl) | 2020-10-07 | 2021-10-07 | Zastosowanie soli siarczanowych n‐(3‐(4‐(3‐(diizobutyloamino)propylo)piperazyn‐1‐ylo)propylo)‐1h‐benzo[d]imidazolo‐2‐aminy i ich solwatów do leczenia chorób neuronu ruchowego i zaburzeń płytki nerwowo-mięśniowej |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20230364076A1 (pl) |
| EP (1) | EP4225306B1 (pl) |
| JP (1) | JP7500875B2 (pl) |
| KR (1) | KR102873128B1 (pl) |
| CN (1) | CN116419756B (pl) |
| AU (1) | AU2021356110B2 (pl) |
| DK (1) | DK4225306T3 (pl) |
| ES (1) | ES3019615T3 (pl) |
| IL (1) | IL301633A (pl) |
| MX (1) | MX2023003715A (pl) |
| PL (1) | PL4225306T3 (pl) |
| PT (1) | PT4225306T (pl) |
| WO (1) | WO2022074093A1 (pl) |
| ZA (1) | ZA202303271B (pl) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20240128694A (ko) * | 2021-12-20 | 2024-08-26 | 알즈프로텍트 | 운동 뉴런 질환 및 신경근 접합부 장애의 치료를 위한 N-(3-(4-(3-(디이소부틸아미노)프로필)피페라진-1-일)프로필)-1H-벤조[d]이미다졸-2-아민 숙시네이트 염 및 이의 용매화물의 사용 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1809288T3 (pl) * | 2004-11-10 | 2012-04-30 | Inst Nat Sante Rech Med | Zastosowanie pochodnych 1,4-bis-(3-aminoalkilo)piperazyny do leczenia chorób neurodegeneracyjnych |
| US7541371B2 (en) * | 2006-02-20 | 2009-06-02 | Eisai R&D Management Co., Ltd. | Method for treating a motor neuron disease |
| CA2895285C (en) * | 2012-12-27 | 2021-03-30 | Alzprotect | Sulphate salts of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine, preparation thereof and use of the same |
| WO2014111525A2 (en) * | 2013-01-18 | 2014-07-24 | Anaxomics Biotech, Sl | New combination therapies for treating nervous system diseases |
| US20150366847A1 (en) * | 2014-06-20 | 2015-12-24 | Medicinova, Inc. | Combination of geranylgeranylacetone and ibudilast and methods of using same |
| CN107466292B (zh) | 2015-03-16 | 2020-05-01 | 国家医疗保健研究所 | 新型1,4-双(3-氨基丙基)哌嗪衍生物及其用途 |
| AU2017286653B2 (en) * | 2016-06-16 | 2021-11-04 | Denali Therapeutics Inc. | Pyrimidin-2-ylamino-1H-pyrazols as LRRK2 inhibitors for use in the treatment of neurodegenerative disorders |
-
2021
- 2021-10-07 DK DK21782766.6T patent/DK4225306T3/da active
- 2021-10-07 EP EP21782766.6A patent/EP4225306B1/en active Active
- 2021-10-07 PT PT217827666T patent/PT4225306T/pt unknown
- 2021-10-07 US US18/044,697 patent/US20230364076A1/en active Pending
- 2021-10-07 PL PL21782766.6T patent/PL4225306T3/pl unknown
- 2021-10-07 WO PCT/EP2021/077641 patent/WO2022074093A1/en not_active Ceased
- 2021-10-07 JP JP2023521379A patent/JP7500875B2/ja active Active
- 2021-10-07 ES ES21782766T patent/ES3019615T3/es active Active
- 2021-10-07 MX MX2023003715A patent/MX2023003715A/es unknown
- 2021-10-07 IL IL301633A patent/IL301633A/en unknown
- 2021-10-07 AU AU2021356110A patent/AU2021356110B2/en active Active
- 2021-10-07 CN CN202180065582.XA patent/CN116419756B/zh active Active
- 2021-10-07 KR KR1020237015438A patent/KR102873128B1/ko active Active
-
2023
- 2023-03-02 ZA ZA2023/03271A patent/ZA202303271B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230083330A (ko) | 2023-06-09 |
| AU2021356110B2 (en) | 2024-07-04 |
| ZA202303271B (en) | 2025-07-30 |
| WO2022074093A1 (en) | 2022-04-14 |
| US20230364076A1 (en) | 2023-11-16 |
| DK4225306T3 (da) | 2025-03-24 |
| AU2021356110A1 (en) | 2023-03-16 |
| EP4225306A1 (en) | 2023-08-16 |
| CN116419756B (zh) | 2025-04-01 |
| NZ797236A (en) | 2025-06-27 |
| JP2023544429A (ja) | 2023-10-23 |
| JP7500875B2 (ja) | 2024-06-17 |
| IL301633A (en) | 2023-05-01 |
| EP4225306B1 (en) | 2025-02-12 |
| PT4225306T (pt) | 2025-04-03 |
| KR102873128B1 (ko) | 2025-10-17 |
| ES3019615T3 (en) | 2025-05-20 |
| CA3191189A1 (en) | 2022-04-14 |
| CN116419756A (zh) | 2023-07-11 |
| MX2023003715A (es) | 2023-04-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL4225306T3 (pl) | Zastosowanie soli siarczanowych n‐(3‐(4‐(3‐(diizobutyloamino)propylo)piperazyn‐1‐ylo)propylo)‐1h‐benzo[d]imidazolo‐2‐aminy i ich solwatów do leczenia chorób neuronu ruchowego i zaburzeń płytki nerwowo-mięśniowej | |
| EP4166550A4 (en) | PHTHALAZINONE COMPOUND, ITS PREPARATION PROCESS AND ITS MEDICAL USE | |
| NZ616828A (en) | Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases | |
| JP2010504342A5 (pl) | ||
| JP2012510989A5 (pl) | ||
| NZ614305A (en) | Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases | |
| MY145001A (en) | Histamine-3 receptor antagonists | |
| NZ599577A (en) | Substituted benzamide derivatives | |
| CN1269483C (zh) | 新用途 | |
| JP2010535816A5 (pl) | ||
| JP2015517981A5 (pl) | ||
| HUP9902808A2 (hu) | 5-(2-(4-(1,2-Benzizotiazol-3-il)-1-piperazinil)-etil)-6-klór-1,3-dihidro-2-(1H)-indol-2-on (ziprazidon) mezilát-trihidrát sói, a vegyületek előállítása és dopamin D2 antagonistaként történő alkalmazása | |
| NZ595248A (en) | Cyclopropyl amide derivatives targeting the histamine h3 receptor | |
| EP3541790C0 (en) | 3-(2-(4-PHENYLPIPERAZIN-1-YL)ETHYL)-2-OXA-8-AZASPIRO[4.5]DECAN-1-ONE DERIVATIVES AND SIMILAR COMPOUNDS AS 5-HYDROXYTRYPTAMINE (5-HT7) RECEPTOR 7 MODULATORS FOR THE TREATMENT OF PE, INFLAMMATORY BOWEL DISEASE, CIRCADIAN RHYTHM DISORDER, OR DEPRESSION | |
| JP2010527984A5 (pl) | ||
| EP3768836C0 (en) | ANIMAL MODEL OF ALZHEIMER’S DISEASE AND ITS USE | |
| EP3856168A4 (en) | COMPOSITION AND USE FOR THE TREATMENT OF PARKINSON'S DISEASE AND RELATED DISORDERS | |
| RU2005136535A (ru) | Новые азетидиновые соединения | |
| EP4380588A4 (en) | PSYCHOACTIVE DRUGS AND THEIR USE FOR THE TREATMENT OF PATHOLOGICAL CONDITIONS AND PSYCHIATRIC AND NEUROLOGICAL DISORDERS | |
| NZ708959A (en) | Sulphate salts of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine, preparation thereof and use of the same | |
| HK40113665A (en) | Use of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine succinate salts and solvates thereof for the treatment of motor neuron diseases and neuromuscular junction disorders | |
| NZ595797A (en) | 2,5-disubstituted arylsulfonamide ccr3 antagonists | |
| HK40121513A (en) | Use of n-(3-(4-(3-(diisobutylamino)propyl)piperazin-1-yl)propyl)-1h-benzo[d]imidazol-2-amine salts and solvates thereof for the treatment of sensory neuron diseases | |
| NZ591896A (en) | Compositions and methods of treating amyloid disease | |
| IL313904A (en) | Heteroalicyclic derivatives and their use in the treatment of cns disorders |